Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + G-CSF + plerixafor
- Development stage
- Unknown
- Lead developer
- IRCCS Ospedale San Raffaele
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination regimen consists of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen, the granulocyte colony-stimulating factor (G-CSF) analog lenograstim (Myelostim), and the CXCR4 antagonist plerixafor (Mozobil). It is being investigated by IRCCS San Raffaele for the mobilization of hematopoietic stem cells (HSCs) in patients with X-linked Chronic Granulomatous Disease (X-CGD). In X-CGD, standard mobilization with G-CSF alone is often suboptimal or associated with inflammatory flares; the addition of ibuprofen is intended to enhance mobilization and potentially mitigate inflammation by inhibiting cyclooxygenase (COX) and reducing prostaglandin E2 (PGE2) levels, which are known to influence HSC retention in the bone marrow niche.
- Other names
- IBU + G-CSF + PlerixaforIbuprofen + Myelostim + MozobilIbuprofen + G-CSF + Plerixafor mobilization regimen
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on ibuprofen + G-CSF + plerixafor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + G-CSF + plerixafor.